<DOC>
	<DOC>NCT01797055</DOC>
	<brief_summary>Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein transferrin. No regular treatment is available for these patients. The objective of this study is to investigate the pharmacokinetics, efficacy and safety of Apotransferrin replacement therapy in atransferrinemia patients.</brief_summary>
	<brief_title>Apotransferrin in Atransferrinemia</brief_title>
	<detailed_description />
	<mesh_term>Metal Metabolism, Inborn Errors</mesh_term>
	<criteria>Established diagnosis of atransferrinemia, defined as serum levels of transferrin below 40 mg/dl Informed consent Known with allergic reactions against human plasma or plasma products Having detectable antiimmunoglobulin A antibodies</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>transferrin</keyword>
	<keyword>anemia</keyword>
	<keyword>iron overload</keyword>
</DOC>